BACKGROUND: Maximum, mean and peak SUV of primary tumor at baseline FDG-PET scans, have often been found predictive for overall survival in non-small cell lung cancer (NSCLC) patients. In this study we further investigated the prognostic power of advanced metabolic metrics derived from intensity volume histograms (IVH) extracted from PET imaging. METHODS: A cohort of 220 NSCLC patients (mean age, 66.6 years; 149 men, 71 women), stages I-IIIB, treated with radiotherapy with curative intent were included (NCT00522639). Each patient underwent standardized pre-treatment CT-PET imaging. Primary GTV was delineated by an experienced radiation oncologist on CT-PET images. Common PET descriptors such as maximum, mean and peak SUV, and metabolic tumor volume (MTV) were quantified. Advanced descriptors of metabolic activity were quantified by IVH. These comprised five groups of features: absolute and relative volume above relative intensity threshold (AVRI and RVRI), absolute and relative volume above absolute intensity threshold (AVAI and RVAI), and absolute intensity above relative volume threshold (AIRV). MTV was derived from the IVH curves for volumes with SUV above 2.5, 3 and 4, and of 40% and 50% maximum SUV. Univariable analysis using Cox Proportional Hazard Regression was performed for overall survival assessment. RESULTS: Relative volume above higher SUV (80%) was an independent predictor of OS (p = 0.05). None of the possible surrogates for MTV based on volumes above SUV of 3, 40% and 50% of maximum SUV showed significant associations with OS [p (AVAI3) = 0.10, p (AVAI4) = 0.22, p (AVRI40%) = 0.15, p (AVRI50%) = 0.17]. Maximum and peak SUV (r = 0.99) revealed no prognostic value for OS [p (maximum SUV) = 0.20, p (peak SUV) = 0.22]. CONCLUSIONS: New methods using more advanced imaging features extracted from PET were analyzed. Best prognostic value for OS of NSCLC patients was found for relative portions of the tumor above higher uptakes (80% SUV).
BACKGROUND: Maximum, mean and peak SUV of primary tumor at baseline FDG-PET scans, have often been found predictive for overall survival in non-small cell lung cancer (NSCLC) patients. In this study we further investigated the prognostic power of advanced metabolic metrics derived from intensity volume histograms (IVH) extracted from PET imaging. METHODS: A cohort of 220 NSCLCpatients (mean age, 66.6 years; 149 men, 71 women), stages I-IIIB, treated with radiotherapy with curative intent were included (NCT00522639). Each patient underwent standardized pre-treatment CT-PET imaging. Primary GTV was delineated by an experienced radiation oncologist on CT-PET images. Common PET descriptors such as maximum, mean and peak SUV, and metabolic tumor volume (MTV) were quantified. Advanced descriptors of metabolic activity were quantified by IVH. These comprised five groups of features: absolute and relative volume above relative intensity threshold (AVRI and RVRI), absolute and relative volume above absolute intensity threshold (AVAI and RVAI), and absolute intensity above relative volume threshold (AIRV). MTV was derived from the IVH curves for volumes with SUV above 2.5, 3 and 4, and of 40% and 50% maximum SUV. Univariable analysis using Cox Proportional Hazard Regression was performed for overall survival assessment. RESULTS: Relative volume above higher SUV (80%) was an independent predictor of OS (p = 0.05). None of the possible surrogates for MTV based on volumes above SUV of 3, 40% and 50% of maximum SUV showed significant associations with OS [p (AVAI3) = 0.10, p (AVAI4) = 0.22, p (AVRI40%) = 0.15, p (AVRI50%) = 0.17]. Maximum and peak SUV (r = 0.99) revealed no prognostic value for OS [p (maximum SUV) = 0.20, p (peak SUV) = 0.22]. CONCLUSIONS: New methods using more advanced imaging features extracted from PET were analyzed. Best prognostic value for OS of NSCLCpatients was found for relative portions of the tumor above higher uptakes (80% SUV).
Authors: Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim Journal: Eur J Nucl Med Mol Imaging Date: 2008-08-15 Impact factor: 9.236
Authors: Philippe Lambin; Ruud G P M van Stiphout; Maud H W Starmans; Emmanuel Rios-Velazquez; Georgi Nalbantov; Hugo J W L Aerts; Erik Roelofs; Wouter van Elmpt; Paul C Boutros; Pierluigi Granone; Vincenzo Valentini; Adrian C Begg; Dirk De Ruysscher; Andre Dekker Journal: Nat Rev Clin Oncol Date: 2012-11-20 Impact factor: 66.675
Authors: Juha T Kauppi; Niku Oksala; Jarmo A Salo; Heikki Helin; Lauri Karhumäki; Jukka Kemppainen; Eero I Sihvo; Jari V Räsänen Journal: Acta Oncol Date: 2012-01-02 Impact factor: 4.089
Authors: Philippe Lambin; Emmanuel Rios-Velazquez; Ralph Leijenaar; Sara Carvalho; Ruud G P M van Stiphout; Patrick Granton; Catharina M L Zegers; Robert Gillies; Ronald Boellard; André Dekker; Hugo J W L Aerts Journal: Eur J Cancer Date: 2012-01-16 Impact factor: 9.162
Authors: Gary J R Cook; Connie Yip; Muhammad Siddique; Vicky Goh; Sugama Chicklore; Arunabha Roy; Paul Marsden; Shahreen Ahmad; David Landau Journal: J Nucl Med Date: 2012-11-30 Impact factor: 10.057
Authors: Jonathan A Abelson; James D Murphy; Nicholas Trakul; Jose G Bazan; Peter G Maxim; Edward E Graves; Andrew Quon; Quynh-Thu Le; Maximilian Diehn; Billy W Loo Journal: Lung Cancer Date: 2012-09-23 Impact factor: 5.705
Authors: Mohit Agarwal; Govinda Brahmanday; Sunil K Bajaj; K P Ravikrishnan; Ching-Yee Oliver Wong Journal: Eur J Nucl Med Mol Imaging Date: 2009-11-14 Impact factor: 9.236
Authors: Yonglin Pu; James X Zhang; Haiyan Liu; Daniel Appelbaum; Jianfeng Meng; Bill C Penney Journal: Eur J Nucl Med Mol Imaging Date: 2018-06-07 Impact factor: 9.236
Authors: Turkey Refaee; Guangyao Wu; Abdallah Ibrahim; Iva Halilaj; Ralph T H Leijenaar; William Rogers; Hester A Gietema; Lizza E L Hendriks; Philippe Lambin; Henry C Woodruff Journal: Respiration Date: 2020-01-28 Impact factor: 3.580
Authors: Ruben T H M Larue; Lien Van De Voorde; Maaike Berbée; Wouter J C van Elmpt; Ludwig J Dubois; Kranthi M Panth; Sarah G J A Peeters; Ann Claessens; Wendy M J Schreurs; Marius Nap; Fabiënne A R M Warmerdam; Frans L G Erdkamp; Meindert N Sosef; Philippe Lambin Journal: BMC Cancer Date: 2016-08-17 Impact factor: 4.430
Authors: Chintan Parmar; Patrick Grossmann; Derek Rietveld; Michelle M Rietbergen; Philippe Lambin; Hugo J W L Aerts Journal: Front Oncol Date: 2015-12-03 Impact factor: 6.244
Authors: Sara Carvalho; Ralph T H Leijenaar; Esther G C Troost; Janna E van Timmeren; Cary Oberije; Wouter van Elmpt; Lioe-Fee de Geus-Oei; Johan Bussink; Philippe Lambin Journal: PLoS One Date: 2018-03-01 Impact factor: 3.240
Authors: Ralph T H Leijenaar; Georgi Nalbantov; Sara Carvalho; Wouter J C van Elmpt; Esther G C Troost; Ronald Boellaard; Hugo J W L Aerts; Robert J Gillies; Philippe Lambin Journal: Sci Rep Date: 2015-08-05 Impact factor: 4.379